Halozyme Therapeutics Inc. (HALO) at a glance
Halozyme Therapeutics Inc. (HALO) is a mid-cap Healthcare company. It trades at $107.2, with a P/E of 24.4, a 23.1% profit margin and revenue growth of 42.2%. It does not pay a dividend. Vestovix scores it 63/100 overall. Its strongest dimension is Momentum (83/100) and its weakest is Income (40/100). Its volatility is roughly in line with the market.
- Price
- $107.20
- Market cap
- $8.24B
- P/E ratio
- 24.4
- Dividend yield
- None
- Beta
- 0.87
- 52-week range
- $61.23 to $109.66
Value
56
Growth
81
Income
40
Safety
60
Momentum
83
Other Healthcare stocks
See allDHR.PR.A50
Danaher Corp
$1,841.01+0.00%
2.58% yield
LLY68
Eli Lilly and Company
$1,116.20-0.96%
0.57% yield
JNJ61
Johnson & Johnson
$266.20+0.73%
2.18% yield
ABBV46
AbbVie Inc.
$257.12-0.86%
2.96% yield
UNH56
UnitedHealth Group Incorporated
$378.73-0.34%
2.16% yield
MRK60
Merck & Co., Inc.
$144.01-0.98%
2.79% yield
ABT54
Abbott Laboratories
$103.57+0.92%
2.16% yield
AMGN65
Amgen Inc.
$378.21-1.05%
2.76% yield